M 1210
Alternative Names: M-1210Latest Information Update: 29 Apr 2021
At a glance
- Originator Maruho
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Ingrown nails
Most Recent Events
- 07 Apr 2021 M 1210 is available for licensing in World as of 07 Apr 2021. https://www.maruho.co.jp/english/aboutmaruho/activities/randd/index.html
- 01 Sep 2020 Phase-III clinical trials in Ingrown-nails in Japan (Topical) before April 2021 (Maruho pipeline, April 2021)